Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Tepadina

(Thiotepa)

ApprovedSmall molecule

Alnylam Pharmaceuticals

Thiotepa is a chemotherapy drug used to treat certain cancers including breast cancer, ovarian cancer, and bladder cancer. It works by damaging cancer cell DNA to stop them from growing and dividing.[2] Tepadina is currently approved and in use across 50 indications[4].[1]

Tepadina is one of 853 small molecule programs targeting Glioma. It is currently in Approved.

50

Indications

195

Total Trials

47

Active Trials

852

Competitors

4

FDA Applications

NDA/BLA/ANDA regulatory filings

3

Patents

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

Primitive Neuroectodermal TumorActive, not recruiting

Aplastic AnemiaActive, not recruiting

Central Nervous System CancerActive, not recruiting

Unspecified Peripheral T-Cell LymphomaApproved

Anaplastic Large Cell LymphomaActive, not recruiting

Central Nervous System LymphomaApproved

Central Nervous System NeoplasmApproved

Extranodal Nasal NK/T Cell LymphomaApproved

LymphomaActive, not recruiting

GliomaPhase 3

Active, not recruiting

Primitive Neuroectodermal TumorPhase 3

Active, not recruiting

Aplastic AnemiaPhase 2/Phase 3

Active, not recruiting

Central Nervous System CancerPhase 2

Active, not recruiting

Unspecified Peripheral T-Cell LymphomaApproved

Approved

Anaplastic Large Cell LymphomaPreclinical

Active, not recruiting

Central Nervous System LymphomaApproved

Approved

Central Nervous System NeoplasmApproved

Approved

Extranodal Nasal NK/T Cell LymphomaApproved

Approved

LymphomaPhase 2

Active, not recruiting

Showing 10 of 50 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tepadina

Alnylam Pharmaceuticals

Halaven

Tecentriq

Trodelvy

Adriamycin

GGynecologic Oncology Group

Prolia

Gemzar

GGynecologic Oncology Group

DATROWAY

Megace

Bristol-Myers Squibb

Cymbalta

Alnylam Pharmaceuticals

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Relapsed or Refractory

NCT06468267

Phase 2Recruiting

Systemic Sclerosis

NCT03630211

Phase 2Active, not recruiting

Stem Cell Transplant

NCT02861417

Phase 2Active, not recruiting

Neuroblastoma

NCT03786783

Q4 2026

Phase 2Recruiting

Neuroblastoma

NCT02605421

Phase 2Active, not recruiting

Allogeneic Hematopoietic Stem Cell Transplantation

NCT01746849

Clinical

Trials by Indication[1]

Breast Cancer23 trials

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer

Withdrawn·—·Phase 1/2·NCT00006123

Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer

Unknown status·UUniversity of Illinois at Chicago·Phase 1·NCT00002616·36 enrolled

S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

Terminated·SSWOG Cancer Research Network·Phase 3·NCT00002772·602 enrolled

Show 20 more trials

Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00002836·184 enrolled

Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00012311

Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer

Completed·YYale University·Phase 2·NCT00002680·40 enrolled

Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer

Unknown status·SScottish Cancer Therapy Network·Phase 3·NCT00003680·300 enrolled

Biological Therapy in Treating Women With Metastatic Breast Cancer

Unknown status·SSt. Luke's Medical Center·Phase 1/2·NCT00002780·60 enrolled

Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer

Completed·HHerbert Irving Comprehensive Cancer Center·Phase 3·NCT00008203

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00005798·209 enrolled

Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

Completed·—·Phase 2·NCT00182793·32 enrolled

Chemotherapy, Filgrastim, and Stem Cell Transplantation With Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

Completed·NNorthwestern University·Phase 2·NCT00004172

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Completed·HHackensack Meridian Health·Phase 2·NCT00004900

Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer

Completed·RRoswell Park Cancer Institute·Phase 1/2·NCT00003877·30 enrolled

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer

Completed·NNorthwestern University·Phase 1·NCT00004174·30 enrolled

High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer

Completed·UUniversity of Arizona·Phase 2·NCT00003068·30 enrolled

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Completed·HHackensack Meridian Health·Phase 2·NCT00004906

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00003199·50 enrolled

Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

Completed·SScottish Cancer Therapy Network·Phase 3·NCT00002755·600 enrolled

High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast Cancer

Completed·UUNICANCER·Phase 3·NCT00002870·180 enrolled

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer

Completed·FFred Hutchinson Cancer Center·Phase 3·NCT00003972·280 enrolled

Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00429182·32 enrolled

Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer

Completed·—·Phase 2·NCT00004092·72 enrolled

Lymphoma13 trials

Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas

Unknown status·AAzienda Ospedaliera San Giovanni Battista·Phase 2·NCT01786018·42 enrolled

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 2·NCT01511562·113 enrolled

Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT00238433·37 enrolled

Show 10 more trials

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00027937

Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma

Unknown status·HHuiqiang Huang·Phase 1/2·NCT05021770·29 enrolled

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT00621036

Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

Completed·NNew Approaches to Brain Tumor Therapy Consortium·Phase 2·NCT00045539

New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

Completed·IInternational Extranodal Lymphoma Study Group (IELSG)·Phase 2·NCT02329080·79 enrolled

Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

Completed·IInternational Extranodal Lymphoma Study Group (IELSG)·Phase 2·NCT01011920·227 enrolled

Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma

Withdrawn·MMassachusetts General Hospital·Phase 1/2·NCT02724904

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT07257419·60 enrolled

Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma

Not yet recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT07276737·37 enrolled

TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in Lymphoma

Completed·SSheba Medical Center·Phase 2·NCT03346096·50 enrolled

Neuroblastoma12 trials

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT02605421·12 enrolled

Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction

Terminated·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT03165292·34 enrolled

Haploidentical Stem Cell Transplantation in Neuroblastoma

Unknown status·LLund University Hospital·Phase 1·NCT00790413·15 enrolled

Show 9 more trials

Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma

Unknown status·SSamsung Medical Center·Phase 2·NCT03061656·40 enrolled

Multiple Therapies in Treating Patients With Advanced Neuroblastoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00040872

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma

Completed·CChildren's Oncology Group·Phase 2·NCT00017368·42 enrolled

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT04221035·800 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma

Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05303727·64 enrolled

Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma

Completed·SSamsung Medical Center·Phase 2·NCT00793845·40 enrolled

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Recruiting·CChildren's Oncology Group·Phase 3·NCT03126916·750 enrolled

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03786783·42 enrolled

Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

Completed·CChildren's Oncology Group·Phase 3·NCT00567567·665 enrolled

Stem Cell Transplant10 trials

Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00857389·60 enrolled

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Active, not recruiting·DDiane George·Phase 1/2·NCT02061800·14 enrolled

Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00392782·24 enrolled

Show 7 more trials

Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant

Completed·—·Phase 1·NCT00376480·19 enrolled

Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00357396·10 enrolled

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00423514·38 enrolled

Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00112567·20 enrolled

Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Completed·YYale University·Phase 1·NCT00104975·20 enrolled

High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

Completed·RRoswell Park Cancer Institute·N/A·NCT00536601·174 enrolled

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02861417·204 enrolled

Bone Marrow Transplantation9 trials

Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission

Completed·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT00002534

High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00060255·451 enrolled

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002515

Show 6 more trials

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Completed·UUniversity of Maryland, Baltimore·Phase 4·NCT00003398·45 enrolled

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer

Completed·NNYU Langone Health·Phase 1·NCT00025558

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

Recruiting·PPaul Szabolcs·Phase 1/2·NCT03500731·8 enrolled

Reduced Intensity Conditioning (RIC) Regimen and Post-transplant Cyclophosphamide in Haploidentical Bone Marrow Transplantation in in Patients With Poor Prognosis Lymphomas

Unknown status·IIstituto Clinico Humanitas·Phase 2·NCT02049580·47 enrolled

Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

Terminated·LLouisiana State University Health Sciences Center Shreveport·Phase 1/2·NCT00003086·12 enrolled

Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003101·60 enrolled

77 more indications

Stem Cell Transplantation6 trials

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03615105·9 enrolled

High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003173·36 enrolled

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00005092·7 enrolled

Show 3 more trials

Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor

Completed·MMemorial Sloan Kettering Cancer Center·N/A·NCT02880293·44 enrolled

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor

Withdrawn·NNYU Langone Health·Phase 2·NCT00003273

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors

Completed·CChildren's Oncology Group·Phase 1·NCT00003141·94 enrolled

Acute Lymphoblastic Leukemia5 trials

Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission

Completed·CChildren's Oncology Group·Phase 3·NCT00382109·146 enrolled

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

Recruiting·—·Phase 1·NCT06195891·33 enrolled

Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

Completed·NNohla Therapeutics, Inc.·Phase 2·NCT01690520·163 enrolled

Show 2 more trials

Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00002704·156 enrolled

A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT05457556·435 enrolled

Memory5 trials

TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT07052370·30 enrolled

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

Recruiting·WWashington University School of Medicine·Phase 1/2·NCT06158828·68 enrolled

CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML

Completed·RRobert Lowsky·Phase 2·NCT04151706·7 enrolled

Show 2 more trials

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT03849651·69 enrolled

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT02790515·170 enrolled

Germ Cell Tumor5 trials

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors

Terminated·UUNICANCER·Phase 2·NCT00003852·45 enrolled

Chemotherapy, Surgery, Radiation Therapy and Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Primary CNS Germ Cell Tumors

Unknown status·—·Phase 2·NCT00025324

Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor

Unknown status·SSamsung Medical Center·Phase 2·NCT02784054·25 enrolled

Show 2 more trials

Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00432094·23 enrolled

Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors

Completed·CChildren's Oncology Group·Phase 2·NCT00047320·104 enrolled

Hematologic Malignancies4 trials

HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01119066·422 enrolled

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

Withdrawn·BBaptist Health South Florida·Phase 2·NCT04282174

Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies

Completed·UUniversity Hospital Tuebingen·Phase 1/2·NCT00202917·61 enrolled

Show 1 more trial

Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT02199041·24 enrolled

Transplantation4 trials

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01010217·176 enrolled

Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation

Completed·—·Phase 2·NCT03342196·40 enrolled

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation

Recruiting·NNantes University Hospital·Phase 2·NCT06252870·82 enrolled

Show 1 more trial

Pilot Study of Unrelated Cord Blood Transplantation

Terminated·KKing's College Hospital NHS Trust·Phase 2·NCT00916045·40 enrolled

Ovarian Cancer4 trials

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 1/2·NCT00003064·30 enrolled

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer

Completed·GGeorgetown University·Phase 1/2·NCT00003297·50 enrolled

Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00002977·45 enrolled

Show 1 more trial

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00003080

Primitive Neuroectodermal Tumor4 trials

Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Completed·CChildren's Oncology Group·Phase 3·NCT00336024·91 enrolled

Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma

Completed·UUniversitätsklinikum Hamburg-Eppendorf·N/A·NCT00303810·567 enrolled

Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors

Completed·CChildren's Oncology Group·Phase 2·NCT00003846·25 enrolled

Show 1 more trial

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor, or Rhabdomyosarcoma

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00003081·16 enrolled

Leukemia3 trials

CD34+ Transplants for Leukemia and Lymphoma

Not yet recruiting·GGuenther Koehne·Phase 2·NCT05565105·100 enrolled

Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002471

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

Terminated·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00066417·51 enrolled

Allogeneic Stem Cell Transplantation3 trials

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

Recruiting·SSt. Anna Kinderkrebsforschung·Phase 2/3·NCT01949129·1,800 enrolled

Allogeneic Stem Cell Transplantation for Children With CML

Completed·SSt. Anna Kinderkrebsforschung·Phase 2/3·NCT02707393·13 enrolled

Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06807606·35 enrolled

Non-malignant Disorders3 trials

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT03980769·40 enrolled

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Terminated·—·Phase 1/2·NCT00801931·1 enrolled

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

Recruiting·PPaul Szabolcs·Phase 2·NCT01962415·100 enrolled

Hematological Malignancies3 trials

Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

Terminated·—·Phase 2·NCT00593554·9 enrolled

Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT05579769·3 enrolled

VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies

Completed·AAlla Keyzner·Phase 1·NCT03885947·7 enrolled

Sickle Cell Disease3 trials

Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease

Completed·MMonica Bhatia·Phase 1·NCT02867800·24 enrolled

Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow

Completed·EEmory University·Phase 2·NCT02757885·10 enrolled

Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients With Symptomatic Sickle Cell Disease. (BMTCTN1507)

Completed·MMedical College of Wisconsin·Phase 2·NCT03263559·95 enrolled

Bone Marrow Transplant3 trials

A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04872595·59 enrolled

Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps

Terminated·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1/2·NCT01350258·8 enrolled

Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00028730·25 enrolled

Malignant Brain Tumors2 trials

Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors

Unknown status·—·Phase 3·NCT00392886·120 enrolled

Thiotepa and Radiation Therapy in Treating Young Patients With Newly Diagnosed Malignant Brain Tumors

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 2·NCT00313521·30 enrolled

Donor2 trials

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

Terminated·MMemorial Sloan Kettering Cancer Center·N/A·NCT01598025·3 enrolled

URMC Related Haplo-identical Donor BMT

Completed·UUniversity of Rochester·Phase 1·NCT02660281·74 enrolled

Central Nervous System2 trials

Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00867178·33 enrolled

Thiotepa Incorporating TBI/Cy Conditioning Regimen for EBV-HLH With Central Nervous System Involvement

Unknown status·—·N/A·NCT05854225·20 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation2 trials

A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors

Terminated·MMontefiore Medical Center·Phase 1·NCT02653196·1 enrolled

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01746849·82 enrolled

Hematologic Disease2 trials

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT06013423·54 enrolled

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00719888·135 enrolled

Infusion2 trials

Infusion of Expanded Cord Blood T Cells

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT00972101

Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells

Terminated·EEverett Meyer·Phase 1/2·NCT01050764·10 enrolled

Medulloblastoma2 trials

Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma

Terminated·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1/2·NCT02025881·29 enrolled

Combination Chemotherapy, Surgery or Radiation Therapy, and Peripheral Stem Cell Transplant in Treating Patients With Recurrent Medulloblastoma or Primitive Neuroectodermal and Pineal Tumors

Completed·CChildren's Cancer and Leukaemia Group·Phase 2·NCT00025077·50 enrolled

Recurrent or Refractory Solid Tumors2 trials

Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00003899

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors

Terminated·SSeattle Children's Hospital·Phase 1·NCT00003194·24 enrolled

Graft Versus Host Disease2 trials

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT03970096·120 enrolled

Itacitinib for the Prevention of Graft Versus Host Disease

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04859946·31 enrolled

Stem Cell2 trials

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01858740·20 enrolled

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT02220985·84 enrolled

Treatment1 trial

A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

Unknown status·UUniversity of Birmingham·Phase 2/3·NCT04217278·333 enrolled

Blood Disease1 trial

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT00450983·1 enrolled

Safety and Efficacy1 trial

The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07441967·44 enrolled

Acute Myeloid Leukemia1 trial

Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

Withdrawn·EEastern Cooperative Oncology Group·Phase 2·NCT00101140

Brain Tumor1 trial

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Recruiting·CChildren's Oncology Group·Phase 2·NCT04684368·160 enrolled

Relapsed or Refractory Hematologic Malignancies1 trial

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT02259348·12 enrolled

APL1 trial

IS-free Treg HaploHCT

Recruiting·—·Phase 1·NCT04678401·30 enrolled

Osteosarcoma1 trial

Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma

Completed·CCentre Leon Berard·Phase 2·NCT00978471·44 enrolled

Multiple Myeloma1 trial

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00003146

Severe Combined Immunodeficiency1 trial

Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 1/2·NCT03597594·4 enrolled

Advanced Hematologic Malignancies1 trial

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Recruiting·SStanford University·Phase 1·NCT05088356·60 enrolled

Retinoblastoma1 trial

Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Completed·CChildren's Oncology Group·Phase 3·NCT00554788·60 enrolled

Hematologic Cancer1 trial

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT04083170·1 enrolled

Chronic Graft Versus Host Disease1 trial

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT03779854·68 enrolled

Myelodysplastic Syndrome1 trial

T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002718·31 enrolled

Atypical Teratoid/Rhabdoid Tumor1 trial

Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

Completed·CChildren's Oncology Group·Phase 3·NCT00653068·70 enrolled

Acute Leukemia1 trial

Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00462787·23 enrolled

Autologous Stem Cell Transplantation1 trial

Autologous Stem Cell Transplantation for Crohn's Disease

Recruiting·PPaul Szabolcs·Phase 1/2·NCT00692939·20 enrolled

NHL1 trial

Freiburg ZNS-NHL Study

Unknown status·UUniversity Hospital Freiburg·Phase 2·NCT00647049·78 enrolled

Outcome1 trial

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

Recruiting·MM.D. Anderson Cancer Center·Phase 2/3·NCT04708054·324 enrolled

Brain Cancer1 trial

Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT04521946

Glioblastoma Multiforme1 trial

Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors

Completed·NNYU Langone Health·Phase 2·NCT00002619·60 enrolled

Chemotherapy1 trial

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

Recruiting·CC17 Council·Phase 1·NCT06942039·15 enrolled

Peripheral Blood Stem Cell Transplantation1 trial

TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03615144·1 enrolled

Patients With Solid Tumors1 trial

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00003926·13 enrolled

Lymphoid Malignancies1 trial

Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies

Unknown status·SSheba Medical Center·Phase 2·NCT02507479·24 enrolled

Diffuse Large B-Cell Lymphoma1 trial

CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant

Recruiting·WWashington University School of Medicine·Phase 2·NCT06687772·36 enrolled

Solid Tumors1 trial

MT2004-30: Tomotherapy for Solid Tumors

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00623077·23 enrolled

Unilateral Retinoblastoma1 trial

Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)

Active, not recruiting·IInstitut Curie·Phase 2·NCT02870907·195 enrolled

Central Nervous System Cancer1 trial

Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer

Completed·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00007982·30 enrolled

Hematopoietic Stem Cell Transplantation1 trial

Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT00824135·34 enrolled

Malignant Glioma1 trial

Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma

Completed·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00008008·40 enrolled

Glioma1 trial

High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas

Completed·CChildren's Oncology Group·Phase 3·NCT00078988·1 enrolled

aGVHD Prophylaxis1 trial

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

Recruiting·LLeland Metheny·Phase 2·NCT06680661·20 enrolled

Bone Marrow Failure Syndrome1 trial

Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease

Completed·UUniversity of California, San Francisco·Phase 1·NCT00295971·21 enrolled

Hemoglobinopathies1 trial

Allo HSCT for High Risk Hemoglobinopathies

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT06872333·62 enrolled

Prevention1 trial

Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT00914940·41 enrolled

Anaplastic Large Cell Lymphoma1 trial

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

Unknown status·EEuropean Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma·N/A·NCT00317408·96 enrolled

Relapsed or Refractory1 trial

RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.

Recruiting·XXianmin Song, MD·Phase 2·NCT06468267·50 enrolled

Randomized1 trial

Randomized Double Cord Blood Transplant Study

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00067002·110 enrolled

Aplastic Anemia1 trial

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

Completed·RRoswell Park Cancer Institute·Phase 2/3·NCT00003816·361 enrolled

Systemic Sclerosis1 trial

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

Recruiting·PPaul Szabolcs·Phase 2·NCT03630211·8 enrolled

Malignant Disease1 trial

Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00038857·29 enrolled

Recurrent or Refractory1 trial

Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT04530487·1 enrolled

Hematologic Malignancy1 trial

Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT01807611·82 enrolled

CNS Tumors1 trial

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

Completed·MMasonic Cancer Center, University of Minnesota·N/A·NCT01505569·44 enrolled

Hematopoietic Stem Cell Transplant1 trial

Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients

Completed·UUniversity of California, San Francisco··NCT03609840·25 enrolled

Soft Tissue Sarcoma1 trial

Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma

Unknown status·SSamsung Medical Center·Phase 2·NCT02784015·41 enrolled

Ganglioneuroblastoma, Nodular1 trial

A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma

Recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT06172296·478 enrolled

Acute Biphenotypic Leukemia1 trial

Pilot Study: Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells (Dilanubicel) in the Setting of Single Cord Blood Transplantation for Patients With Hematologic Malignancies

Active, not recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT03399773·31 enrolled

Sickle Cell Anemia1 trial

T-Cell Depleted, Alternative Donor Transplant in Pediatric and Adult Patients With Severe Sickle Cell Disease (SCD) and Other Transfusion-Dependent Anemias

Recruiting·PPaul Szabolcs·Preclinical·NCT03653338·5 enrolled

Acute Lymphocytic Leukemia (ALL)1 trial

Phase 1 Trial of Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies

Recruiting·SSawa Ito, MD·Phase 1·NCT07565220·48 enrolled

Unspecified1 trial

T&B Depletion Non Malignant

Unknown status·FFranco Locatelli·Phase 2·NCT01810926·130 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

THIOTEPA

NDA NDA011683

Dec 22, 1994

THIOPLEX

NDA NDA020058

Jan 26, 2017

TEPADINA

NDA NDA208264

Jun 25, 2024

TEPYLUTE

NDA NDA216984

Sources

References

[1]
ClinicalTrials.gov — 195 trial records for Thiotepa. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Tepadina drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Thiotepa compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Thiotepa. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA216984). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Tepadina. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Alnylam Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Alnylam Pharmaceuticals

Patent Landscape[6]

Patent Cliff

May 31, 2037

Earliest patent expiration — generic entry possible after this date

Patent #Expires

9931458May 31, 2037

11975013Aug 16, 2041

12622921Aug 16, 2041

Related News